Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients Horn, L., Wu, Y., Reck, M., Wakelee, H., Liang, C., Harrow, K., Oertel, V., Mok, T. OXFORD UNIV PRESS. 2018
View details for Web of Science ID 000459277303270